Related Experiment Videos
Motexafin gadolinium: a possible new radiosensitiser
1Dr B Verbeeten Institute, PO Box 90120, 5000 LA Tilburg, The Netherlands.
Expert Opinion on Investigational Drugs
|July 2, 2003
Summary
Motexafin gadolinium (MGd) enhances radiation therapy effectiveness, particularly for brain metastases. This redox-active drug shows promise in cancer treatment with manageable side effects.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Background:
- Motexafin gadolinium (MGd) is a redox-active metallotexaphyrin targeting tumor cells.
- MGd demonstrates potential as a radiosensitizer, enhancing radiation therapy efficacy.
- Preclinical models indicated radiation enhancement following MGd administration.
Purpose of the Study:
- To evaluate the safety and efficacy of Motexafin gadolinium (MGd) as a radiosensitizer.
- To assess MGd's impact on time to neurological progression in brain metastases.
- To explore MGd's therapeutic potential in glioblastoma multiforme treatment.
Main Methods:
- Phase I, II, and III clinical trials were conducted.
- Studies involved administration of MGd followed by radiotherapy.
- Patient outcomes, including neurological progression and survival, were monitored.
Main Results:
- MGd was well-tolerated with a maximum-tolerated dose of 6.3 mg/kg.
- Reversible side effects included sclera, skin, and urine discoloration.
- Phase III trial showed improved time to neurological progression for lung cancer brain metastases with MGd plus radiation.
- Phase I trial for glioblastoma multiforme indicated a median survival of 17.3 months.
Conclusions:
- Motexafin gadolinium (MGd) is a well-tolerated radiosensitizer with demonstrated clinical efficacy.
- MGd shows significant benefit in managing brain metastases, particularly for lung cancer.
- Further research into MGd combined with radiotherapy is warranted for glioblastoma and other cancers.